Post Market Analysis of Toxicities Reported with Chimeric Antigen Receptor (CAR) T-Cell Therapies and Bispecific T-Cell Engager (BiTE) for Diffuse Large B-Cell Lymphoma (DLBCL) Using the FDA Adverse Event Reporting System (FAERS)
Noah Giese, Cornelius Rosenbaum, Kunal Jain, Parth Malaviya et autres
CAR-T and BiTE therapies have improved outcomes in relapsed/refractory (r/r) DLBCL . However, they are associated with unique and potentially severe adverse events (AE) that impact morbidity and mortality. The aim of this study is to compare toxicities and outcomes in patients …
us (code pays fourni par la source)
1 citation
Transplantation and Cellular Therapy